

The Onychomycosis Market (2018 Edition)

September 2018



The US Onychomycosis Market: Coverage

Executive Summary and Scope

Introduction/Market Overview

Global Market Analysis

The US Market Analysis

Competitive Landscape

Company Profiling

The US Onychomycosis Market: Coverage

Scope of the Report

Attributes	Details
Title	The US Onychomycosis Market: (2018 Edition)
Coverage	Global and Regional
Forecast Period of Market	2018-2022
Competition in the Market	Fragmented
Key Players	Valeant Pharmaceuticals, Pfizer Inc., Novartis AG, Johnson & Johnson

The US Onychomycosis Market

Executive Summary

Onychomycosis is a condition of fungal nail infection. Onychomycosis begins in the nail bed and progresses to the nail plate, causing the nail to become discolored, deformed, and even separated from the nail bed. Onychomycosis has a significant chance of recurrence. Of all the nail abnormalities in the world, around 50% are the case of onychomycosis. In most of the cases it occurs in the toenails. Onychomycosis is not a life threatening disease but, may persist or worsen if not treated.


Symptoms of onychomycosis are changes in appearance of the nail, interference with standing, walking, and exercising, pain, discomfort, etc. The causative pathogens of onychomycosis include dermatophytes (most common), Candida, and nondermatophytic molds.

There are five types of Onychomycosis: Distal Subungual Onychomycosis, White superficial onychomycosis, Proximal subungual onychomycosis, Endonyx onychomycosis and Candidal onychomycosis. Two types of treatments are available of onychomycosis: Oral Treatment and Topical Treatment. Oral treatment includes: Terbinafine, Itraconazole, etc. and topical treatment includes Kerydin, Jublia, etc. Nonpharmacologic approaches are also there, which includes the following: Laser treatment, Photodynamic therapy, etc.

The US onychomycosis market (prescription drugs) has increased with a healthy growth rate over the years and is expected to increase further during the forecasted period. The US onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc.

Skin Infections Drugs Market: Global Analysis

Global Skin Infections Market by Value



CAGRs

2018-2026

xx%

The global skin infection drugs market was valued at ... billion in 2017. The market is further estimated to reach to US\$... Billion by 2026 compared to US\$... Billion by 2018 showcasing a CAGR of ... over the years 2018-2026.

Skin Infection Market: Product Analysis

Global Skin Infections Market by Products; 2017




Drugs for Onychomycosis (Kerydin and Jublia) , xx%


Other Skin Infection Drugs, xx%

Skin Infection Drugs Market: Product Analysis

Global Kerydin Drugs Market by Value




Global Jublia Drugs Market by Value




Product	CAGR
	2018-2026
Kerydin	xx%
Jublia	xx%

Onychomycosis Market: Pipeline Drugs Analysis

Phase II Drugs (Onychomycosis) Pipeline Forecast



Phase III Drugs (Onychomycosis) Pipeline Forecast




The onychomycosis is a part of skin infection. The phase-II drugs of the onychomycosis that are in the pipeline are projected to reach a market value worth of US\$... million by 2026. Currently, there are three drug molecules in Phase II clinical trials for treatment of Onychomycosis. The Phase II drugs are VT-1161 (Viamet), Novexatin (NovaBiotics) and topical NO2 (Novan Therapeutics)

The phase-III drugs of the onychomycosis that are in the pipeline are projected to reach a market value worth of US\$... million by 2026 from US\$... million in 2018. Currently there are three drug molecules in Phase III clinical trials for treatment of Onychomycosis. The Phase III drugs are P-3058 (Polichem), TDT 067 (Celtic Pharma) and MB015 (Moberg Pharma).

The US Nail Care Market: An Analysis

The US Nail Care Market by Value




The US nail care market by value was US\$... million in the month of April 2017, up from US\$... million in March 2017. The nailcare market includes drugs for onychomycosis.

Factors such as increasing per capita healthcare spending, rising aging population, consumers' disposition towards maintaining aesthetic appearing nails, and growing product innovation are also expected to support the growth of the nailcare market in the future.


The US Nail Care Market: An Analysis

The US Nail Care Market Segments; 2017




The US Nail Care Market: Segment Analysis

The US Kerydin Drugs Market by Value




The US Jublia Drugs Market by Value



The US Kerydin drug market is estimated to have valued US\$100.2 million in the 1Q2016 as compared to US\$84.9 million in the 4Q2015. The US Jublia drug market value has declined from US\$39 million in 3Q2016 to US\$19 million in 3Q2017.

The US Onychomycosis Market: An Analysis

The US Onychomycosis Market by Prevalence; 2016



Prevalence Type	Prevalence Population (Million)
People with Onychomycosis	...
Condition diagnosed by Physicians	...
Actively Treated	...

The US Onychomycosis Market: Competitive Landscape

Players Profiled

- Valeant Pharmaceuticals



- Pfizer Inc.



- Johnson & Johnson



- Novartis AG



Note: The above graphs are for pictorial representation only